This triple-action mechanism distinguishes it from existing approved agents such as semaglutide (a GLP-1 receptor agonist, approved in the UK as Wegovy and Ozempic) and tirzepatide (a dual GIP/GLP-1 receptor agonist, approved as Mounjaro), and is being studied primarily for obesity and type 2 diabetes management
Additionally, it supports cardiovascular health and increasing aerobic capacity during exercise
Low energy levels or unexplained fatigue are common problems that can be attributed to a wide range of factors, including but not limited to a stressful lifestyle, various chronic diseases, sleep problems, and inadequate intake of essential nutrients
We have the opportunity to help halt this progression by providing a more natural and proactive alternative with Eriomin. IBN formulates, manufactures and markets science-based ingredients, proprietary extracts and formula innovations for applications in dietary supplements, functional foods and beverages, cosmetics and animal nutrition